AUTHOR=Yang Wuxia , Zhang Yichao , Gao Jing , Hu Pengcheng , Yang Yanjie , Xu Xiaoqing 

TITLE=A meta-analysis of the Zilongjin tablets for non-small cell lung cancer and its network pharmacology of action against NSCLC and COVID-19

JOURNAL=Frontiers in Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1080121

DOI=10.3389/fmed.2023.1080121

ISSN=2296-858X

ABSTRACT=OBJECTIVE  To objectively evaluate the efficacy of Zilongjin tablets in non-small cell lung cancer (NSCLC) and to explore its potential mechanism of action against NSCLC and COVID-19 based on network pharmacology.
METHODS  The database was searched for randomized controlled trials (RCTs) of Zilongjin tablets for NSCLC published up to 22 August 2022. The quality of included trials was assessed using Cochrane standard guidelines, and a meta-analysis was performed using Rev Man 5.3. Gene targets for intersections of NSCLC and COVID-19 (NC) and drugs were obtained from the TCMSP database, HERB database, GeneCards database, and NCBI database for network pharmacology research.
RESULTS  Meta-analysis included 14 articles with 2430 patients. The meta-analysis showed that Zilongjin Tablets combined with conventional chemotherapy were significantly more effective than chemotherapy alone in the treatment of NSCLC. A total of 29 drug-disease intersecting targets were identified in the network pharmacology. The 'ingredient-target-pathway' diagram C-P network contained 119 nodes and 429 edges, with the majority of targets associated with inflammatory responses.
CONCLUSION  The efficacy and quality of life of Zilongjin Tablets combined conventional chemotherapy for NSCLC were significantly better than chemotherapy alone, alleviating various adverse effects. At the same time, Zilongjin Tablets may modulate the inflammatory response to alleviate NSCLC and COVID-19.